Your shopping cart is currently empty

PAF (C16) is a potent MAPK and MEK/ERK activator that induces increased vascular permeability. PAF (C16) (PAF (C16)) is a platelet-activating factor, a phospholipid-derived mediator and a ligand for PAF G protein-coupled receptor (PAFR). PAF (C16) has shown anti-apoptotic and anti-inflammatory activity in vitro, inhibiting Caspase-dependent apoptosis by interacting with its receptor (PAF-R) to perform cell signaling.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $35 | - | In Stock | |
| 5 mg | $81 | - | In Stock | |
| 10 mg | $143 | - | In Stock | |
| 25 mg | $318 | - | In Stock | |
| 50 mg | $538 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $93 | - | In Stock |
| Description | PAF (C16) is a potent MAPK and MEK/ERK activator that induces increased vascular permeability. PAF (C16) (PAF (C16)) is a platelet-activating factor, a phospholipid-derived mediator and a ligand for PAF G protein-coupled receptor (PAFR). PAF (C16) has shown anti-apoptotic and anti-inflammatory activity in vitro, inhibiting Caspase-dependent apoptosis by interacting with its receptor (PAF-R) to perform cell signaling. |
| In vitro | In PAFR+/+ cultures, C16-PAF (PAF (C16); 0.5-1.5 μM; for 24 hours) does not elicit significant concentration-dependent neuronal loss, whereas it does induce significant concentration-dependent neuronal loss in PAFR?/? cultures. Specifically, C16-PAF (1 μM) induces neuronal death in PAFR?/? cells infected with EGFP alone[1].In PAFR neurons, C16-PAF (1 μM; for 24 hours) activates caspase 7 but not caspase 3[1]. Synthesized by two distinct pathways, the remodeling pathway and the de novo synthesis pathway, C16-PAF acts by binding to a unique G-protein-coupled seven-transmembrane receptor[2][3]. Furthermore, C16-PAF (1-25 μg/ml; 6, 12, 24 h) exhibits time-dependent inhibition of M. smegmatis and M. bovis BCG growth[3]. |
| Synonyms | C16-PAF |
| Molecular Weight | 523.68 |
| Formula | C26H54NO7P |
| Cas No. | 74389-68-7 |
| Smiles | [C@H](COP(OCC[N+](C)(C)C)(=O)[O-])(COCCCCCCCCCCCCCCCC)OC(C)=O |
| Relative Density. | no data available |
| Storage | store at low temperature | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||
| Solubility Information | H2O: 30 mg/mL (57.29 mM), Sonication is recommended. DMSO: 40 mg/mL (76.38 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween-80+45% Saline: 2 mg/mL (3.82 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
H2O/DMSO
| |||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.